FDA Advisory Committee Votes Against Capricor's Deramiocel for Duchenne Cardiomyopathy: What the Decision Means

The U.S. Food and Drug Administration (FDA)'s Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against recommending approval of Capricor Therapeutics' investigational cell therapy deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), concluding that the available clinical evidence did not establish sufficient effectiveness for the proposed indication.

Although the committee's recommendation is nonbinding, it represents a significant regulatory hurdle ahead of the FDA's final decision on Capricor's biologics license application. The agency is expected to announce its decision by August 22, 2026, the Prescription Drug User Fee Act (PDUFA) target action date.

The advisory committee's discussion focused on whether the Phase 3 HOPE-3 trial provided sufficient evidence that deramiocel improves cardiac outcomes in patients with Duchenne-associated cardiomyopathy. While several members acknowledged the urgent need for new therapies, most concluded that the efficacy data were not sufficiently robust because the findings depended heavily on the statistical methods used to analyze the trial.

Capricor disagreed with the committee's interpretation of the evidence. The company stated that the HOPE-3 trial supported the therapy's effectiveness and maintained that the FDA relied on an earlier draft of the study's statistical analysis plan rather than the final version that had been completed before trial unblinding. Following the meeting, Capricor said it remains committed to working with the FDA ahead of the August regulatory decision and continues to believe deramiocel could benefit patients with Duchenne muscular dystrophy.

The meeting has attracted attention beyond a single investigational therapy because it highlights the scientific and regulatory challenges involved in evaluating advanced cell therapies for rare diseases. It also illustrates how differences in statistical analysis and clinical trial interpretation can influence regulatory decisions, even when an unmet medical need exists.

Why Did the FDA Advisory Committee Vote Against Approval?

Although advisory committee members recognized the significant unmet need faced by patients with Duchenne muscular dystrophy, most concluded that the available evidence did not provide substantial proof that deramiocel was effective for the proposed indication of Duchenne-associated cardiomyopathy.

The committee's discussion centered on whether the Phase 3 HOPE-3 trial demonstrated a reproducible and clinically meaningful cardiac benefit. FDA reviewers argued that changes made to the study's statistical analysis plan affected how efficacy was assessed and influenced whether the results reached statistical significance.

According to FDA reviewers, Capricor revised important aspects of the trial's statistical analysis, including endpoint definitions, analytical methods, and the handling of missing data. The agency concluded that these changes complicated interpretation of the study and reduced confidence in the reported treatment effect.

Capricor disputed that conclusion throughout the meeting.

The company maintained that its final Statistical Analysis Plan (SAP 3.0) had been finalized before patient data were unblinded and therefore represented the appropriate framework for evaluating the trial. Company representatives argued that the FDA instead relied heavily on an earlier unsigned draft that no longer reflected the finalized study design.

During the meeting, Capricor Chief Executive Officer Linda Marbán, PhD, compared the FDA's approach to "grading a term paper using an unfinished draft rather than the final submitted version."

FDA statisticians disagreed with that characterization, stating that earlier versions of the statistical analysis plan remained broadly consistent with the trial's original design and provided the most appropriate basis for evaluating efficacy.

Several advisory committee members ultimately described the efficacy findings as "fragile," explaining that the apparent treatment benefit depended on the statistical methods used rather than remaining consistent across multiple reasonable analyses. For many members, that uncertainty prevented them from concluding that deramiocel had demonstrated substantial evidence of effectiveness for the proposed cardiac indication.

What Is Deramiocel?

Deramiocel (CAP-1002) is an investigational allogeneic cell therapy developed by Capricor Therapeutics for Duchenne muscular dystrophy.

Unlike gene therapies that aim to replace or repair the defective dystrophin gene, deramiocel does not attempt to restore dystrophin production. Instead, it is designed to reduce inflammation and fibrosis while helping preserve skeletal and cardiac muscle function through the biological activity of specialized heart-derived cells.

How Does Deramiocel Work?

Deramiocel consists of cardiosphere-derived cells (CDCs) obtained from donated human heart tissue. These cells are not intended to replace damaged heart muscle or correct the underlying genetic mutation responsible for Duchenne muscular dystrophy.

Instead, researchers believe the cells work by releasing small extracellular vesicles known as exosomes, which contain proteins, lipids, and genetic material that influence surrounding cells. These exosomes interact with immune cells, particularly macrophages, encouraging them to shift from a pro-inflammatory state toward a tissue-repairing phenotype. Through these immunomodulatory and anti-fibrotic effects, deramiocel is intended to help preserve both skeletal and cardiac muscle function.

The therapy is administered as an intravenous infusion every three months. Unlike gene therapies, which seek to restore dystrophin production, deramiocel is designed to modify the disease environment by reducing inflammation and fibrosis rather than correcting the genetic defect itself.

HOPE-3 Trial: Design, Results, and FDA Review

The advisory committee's review centered on the Phase 3 HOPE-3 trial, which evaluated deramiocel in boys and young men aged 10 years and older with Duchenne muscular dystrophy.

The randomized, double-blind, placebo-controlled study enrolled 106 participants across multiple centers in the United States. Of these, 83 participants had evidence of cardiomyopathy at baseline and were included in the cardiac efficacy analyses.

Capricor reported that deramiocel slowed upper limb disease progression using the Performance of the Upper Limb version 2.0 (PUL 2.0) assessment. The company also reported findings suggesting preservation of cardiac function in certain patient groups, forming the basis of its biologics license application for Duchenne-associated cardiomyopathy.

However, FDA reviewers concluded that the evidence supporting the proposed cardiac indication remained insufficient because the statistical significance of the findings depended on the analytical methods used to evaluate the trial data.

Science Explained: What Is a Statistical Analysis Plan?

A Statistical Analysis Plan (SAP) is a detailed document prepared before researchers analyze the results of a clinical trial. It specifies exactly how the trial data will be evaluated, including the study endpoints, statistical tests, methods for handling missing data, and the patient populations that will be included in different analyses.

Preparing the SAP before trial results are known helps minimize bias. It reduces the possibility of selecting analytical methods after reviewing the data that could make a treatment appear more effective than it actually is.

During the advisory committee meeting, disagreement over different versions of the SAP became the central scientific issue.

FDA reviewers argued that the trial should primarily be interpreted using earlier prespecified analytical methods. Capricor maintained that its final SAP (version 3.0), completed before trial unblinding, represented the scientifically appropriate framework because it reflected protocol updates made during the conduct of the study.

Because these different approaches produced different statistical results, several advisory committee members concluded that the evidence supporting deramiocel's effectiveness was not sufficiently robust for the proposed indication.

Why Did FDA and Capricor Disagree Over the HOPE-3 Data?

The debate surrounding deramiocel was not whether the therapy showed any biological activity, but whether the available clinical evidence met the FDA's regulatory standard for demonstrating effectiveness.

FDA reviewers concluded that the HOPE-3 trial did not meet its original prespecified efficacy endpoints when earlier statistical analyses were applied. They also expressed concern that changes to endpoint definitions, analytical methods, and missing-data handling introduced uncertainty into the interpretation of the results.

Capricor strongly disputed that assessment.

The company argued that scientific and operational changes made during the trial justified updates to the statistical analysis plan before patient data were unblinded. According to Capricor, these revisions reflected accepted clinical trial practice and were completed before investigators knew the study results.

The disagreement extended to both the skeletal muscle and cardiac endpoints. While Capricor reported statistically significant slowing of upper limb disease progression using its preferred analytical approach, FDA reviewers concluded that the trial did not achieve statistical significance when evaluated according to earlier prespecified analyses.

Similarly, Capricor reported evidence suggesting preservation of cardiac function, whereas FDA reviewers concluded that these findings did not demonstrate substantial evidence of effectiveness for Duchenne-associated cardiomyopathy.

Several advisory committee members described the efficacy data as "fragile," explaining that confidence in the findings changed depending on which reasonable statistical assumptions were applied. For many members, this uncertainty prevented them from concluding that the available evidence established a clear and reproducible treatment benefit.

What Is Duchenne Muscular Dystrophy and Why Does Cardiomyopathy Develop?

Duchenne muscular dystrophy is a rare X-linked genetic disorder caused by mutations in the DMD gene, which encodes the protein dystrophin. Without functional dystrophin, muscle fibers become progressively damaged, leading to worsening weakness of skeletal, respiratory, and cardiac muscles.

Although progressive muscle weakness is the hallmark of the disease, cardiac complications become increasingly important as patients grow older. Ongoing damage to the heart muscle can lead to dilated cardiomyopathy, reduced pumping function, heart failure, and premature death.

Today, cardiomyopathy represents one of the leading causes of death among individuals living with Duchenne muscular dystrophy.

Current management includes corticosteroids, respiratory support, physical therapy, and medications such as angiotensin-converting enzyme inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and angiotensin receptor blockers to slow the progression of heart disease. Despite these measures, no therapy has received FDA approval specifically for Duchenne-associated cardiomyopathy, leaving patients and families with limited treatment options.

Did Deramiocel Improve Heart Function?

A major point of discussion during the advisory committee meeting was the therapy's effect on left ventricular ejection fraction (LVEF), a commonly used measure of how efficiently the heart pumps blood with each contraction.

Although changes in LVEF were not the HOPE-3 trial's primary endpoint, they formed the basis of Capricor's application seeking approval for the treatment of Duchenne-associated cardiomyopathy.

Capricor modified its planned analysis before trial unblinding, changing how LVEF would be evaluated. Using its final statistical analysis plan, the company reported findings suggesting a potential cardiac benefit in certain patient groups.

FDA reviewers, however, concluded that these results did not demonstrate statistically significant improvement when evaluated using earlier prespecified analytical methods. They also questioned whether LVEF, as measured in the trial, could serve as a validated surrogate endpoint for meaningful long-term clinical benefit in this patient population.

Several advisory committee members also discussed observations of increased left ventricular volume in some treated participants. While this finding did not establish that deramiocel worsened heart function, members stated that additional investigation would be needed because enlargement of the heart's pumping chamber may indicate disease progression in certain clinical settings.

Did Deramiocel Improve Upper Limb Function?

Although the advisory committee voted against recommending approval for the proposed cardiac indication, several members acknowledged that the upper limb data appeared more encouraging.

The HOPE-3 trial evaluated arm and hand function using the Performance of the Upper Limb version 2.0 (PUL 2.0) assessment, which measures the ability to perform everyday activities such as reaching, lifting objects, and moving the hands and arms. Preserving upper limb function becomes increasingly important as Duchenne muscular dystrophy progresses and mobility declines.

Capricor reported that deramiocel slowed upper limb disease progression by approximately 54% compared with placebo using analyses based on its final statistical analysis plan. Investigators also noted that an improvement of approximately one point on the PUL 2.0 scale is generally considered clinically meaningful.

FDA reviewers maintained that statistical significance for the primary endpoint depended on revised analytical methods introduced during the study. Under the agency's preferred analyses, the trial did not meet its original prespecified primary endpoint.

Despite these differing interpretations, several advisory committee members suggested that upper limb preservation may warrant additional investigation in future studies.

Why This Matters for Patients

For many families living with Duchenne muscular dystrophy, preserving heart function has become an increasingly important treatment goal.

Advances in respiratory care and supportive therapies have helped many individuals with Duchenne live longer than in previous decades. As survival has improved, cardiomyopathy has become one of the leading causes of death in the disease. Slowing the progression of heart muscle damage has therefore become a major focus of clinical research.

At present, clinicians manage Duchenne-associated cardiomyopathy using medications commonly prescribed for heart failure, including ACE inhibitors, beta-blockers, angiotensin receptor blockers, and mineralocorticoid receptor antagonists. However, no therapy has received FDA approval specifically for treating cardiomyopathy in Duchenne muscular dystrophy.

This unmet medical need explains why many patients, caregivers, clinicians, and advocacy organizations closely followed the advisory committee meeting and participated during the public hearing.

What Patients and Families Told the FDA Advisory Committee

During the public hearing portion of the meeting, patients living with Duchenne muscular dystrophy, family members, clinicians, and patient advocates urged regulators to consider the broader clinical context.

Several speakers described preserving upper limb function as an important factor in maintaining independence and quality of life. Some participants who had received deramiocel during clinical trials described improvements they believed were associated with treatment.

The advisory committee acknowledged these experiences and recognized the significant unmet medical need faced by patients with Duchenne muscular dystrophy. At the same time, members emphasized that regulatory approval decisions must be based on evidence demonstrating that a therapy is effective for its proposed indication.

Why FDA Advisory Committee Votes Matter

FDA advisory committees consist of independent experts who review scientific evidence and provide recommendations before the agency reaches a regulatory decision.

Although these recommendations are nonbinding, they frequently influence the FDA's final decision because they represent an independent scientific assessment of the available evidence.

In this case, committee members were asked a narrowly focused question: whether the available evidence demonstrated that deramiocel was effective for treating Duchenne-associated cardiomyopathy. They were not asked to vote on the therapy's overall benefit-risk profile or its potential effects on skeletal muscle function.

The FDA is expected to announce its final decision on Capricor's biologics license application by August 22, 2026.

What the FDA Advisory Committee Vote Means for Regenerative Medicine

The advisory committee's recommendation extends beyond a single investigational therapy.

Cell and gene therapies continue to represent one of the fastest-growing areas of biotechnology, particularly for rare genetic diseases with limited treatment options. Because these therapies often involve complex biological products and relatively small clinical trials, demonstrating convincing clinical benefit can be challenging.

The deramiocel review highlights several broader issues facing regenerative medicine development:

• Designing clinical trials with endpoints that regulators consider clinically meaningful.

• Finalizing statistical analysis plans before trial completion.

• Demonstrating treatment effects that remain consistent across different analytical approaches.

• Balancing urgent unmet medical needs with the regulatory requirement for substantial evidence of effectiveness.

The meeting illustrates that promising biological mechanisms alone are not sufficient for regulatory approval. Sponsors must also demonstrate clear, reproducible clinical benefit through rigorously designed studies.

What Biotechnology Researchers Can Learn

The deramiocel review provides several lessons for researchers developing future regenerative medicine therapies.

Pre-specified analyses matter. Regulatory agencies place considerable importance on analytical methods that are established before study results become available.

Clinical endpoints require careful selection. Outcome measures should reflect meaningful improvements in patient health and daily functioning.

Statistical robustness is essential. Results should remain consistent when evaluated using different scientifically appropriate analytical approaches.

Regulatory communication is important. Differences between sponsors and regulators regarding study design or analytical methods can become central issues during product review.

Rare disease trials present unique challenges. Small patient populations make trial design, endpoint selection, and statistical planning especially important.

What Happens Next?

The advisory committee's recommendation does not represent the FDA's final regulatory decision.

The agency will independently review the advisory committee's recommendations together with the complete clinical and regulatory record before determining whether deramiocel should receive marketing approval for Duchenne-associated cardiomyopathy.

Capricor has stated that it remains committed to pursuing approval and continues to believe that the HOPE-3 trial supports deramiocel's clinical benefit. Company representatives have also indicated that they will continue discussions with the FDA regarding possible regulatory pathways. Following the meeting, Chief Executive Officer Linda Marbán said the company would evaluate additional strategic options if approval is ultimately not granted.

Why This Decision Matters Beyond Capricor

The advisory committee's recommendation has implications beyond a single investigational therapy.

It highlights the increasingly rigorous evidentiary standards applied to regenerative medicine products, particularly therapies intended for rare diseases where clinical trials often involve relatively small patient populations.

The review also demonstrates that regulatory agencies expect biological plausibility to be supported by statistically robust and clinically meaningful evidence before approval. Even when an unmet medical need exists and promising scientific findings are reported, regulators continue to require reproducible data demonstrating that a therapy provides meaningful benefit for the proposed indication.

Future developers of cell and gene therapies are likely to study the deramiocel review closely because it underscores the importance of trial design, endpoint selection, statistical planning, and early engagement with regulatory agencies throughout product development.

Key Takeaways

• The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 against recommending approval of deramiocel for Duchenne muscular dystrophy-associated cardiomyopathy.

• Committee members concluded that the available evidence did not provide substantial evidence of effectiveness for the proposed cardiac indication.

• A major point of disagreement involved interpretation of the HOPE-3 trial's statistical analysis plan.

• Several committee members considered the upper limb findings encouraging but concluded that additional evidence would be needed.

• The FDA's final regulatory decision is expected by August 22, 2026.

• The review highlights broader regulatory challenges facing the development of regenerative medicine therapies.

Why This Story Matters

The advisory committee's recommendation represents more than a regulatory milestone for a single biotechnology company.

It illustrates how scientific evidence, clinical trial methodology, statistical analysis, and regulatory science intersect during the evaluation of advanced cell therapies. The meeting also demonstrates the challenges of developing treatments for rare diseases where patient need is substantial but regulators must still determine whether available evidence meets established approval standards.

For clinicians, researchers, biotechnology students, and patients, the deramiocel review offers an important case study in how innovative regenerative medicine therapies are evaluated before they can become available in clinical practice.

1. Capricor Therapeutics. 2026. "Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel." July 27, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/349/capricor-comments-on-briefing-materials-ahead-of-july-29.

2. Capricor Therapeutics. 2026. "The Lancet Publishes HOPE-3 Data for Capricor Therapeutics' Deramiocel in Duchenne Muscular Dystrophy." July 29, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/350/the-lancet-publishes-hope-3-data-for-capricor.

3. Capricor Therapeutics. 2026. "Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel." July 30, 2026. https://www.capricor.com/investors/news-events/press-releases/detail/351/capricor-therapeutics-provides-update-on-fda-advisory-committee-meeting-for-deramiocel. (Official company press release.)

4. Food and Drug Administration. 2026. Cellular, Tissue, and Gene Therapies Advisory Committee Briefing Document: Deramiocel for Duchenne Muscular Dystrophy. July 29, 2026. https://www.fda.gov/media/193840/download.

5. McDonald, Craig M., Eduardo Marbán, Stephen Hendrix, et al. 2026. "Deramiocel Heart-Derived Cellular Therapy in Advanced Duchenne Muscular Dystrophy (HOPE-3): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial." The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01385-1/fulltext.

6. McDonald, Craig M., Eduardo Marbán, Stephen Hendrix, et al. 2022. "Repeated Intravenous Cardiosphere-Derived Cell Therapy in Late-Stage Duchenne Muscular Dystrophy (HOPE-2): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial." The Lancet 399 (10329): 1049-1058. https://doi.org/10.1016/S0140-6736(22)00012-5.

7. Reuters. 2026. "FDA Panel Votes Against Capricor's Duchenne Heart Disease Therapy." July 29, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/fda-panel-votes-against-capricors-duchenne-heart-disease-therapy-2026-07-29/.

8. Shah, Muhammad N. A., and Toshifumi Yokota. 2023. "Cardiac Therapies for Duchenne Muscular Dystrophy." Therapeutic Advances in Neurological Disorders 16. https://doi.org/10.1177/17562864231185056.

9. El-Aloul, B., L. Altamirano-Diaz, et al. 2017. "Pharmacological Therapy for the Prevention and Management of Cardiomyopathy in Duchenne Muscular Dystrophy: A Systematic Review." Neuromuscular Disorders 27 (1): 4-14. https://doi.org/10.1016/j.nmd.2016.10.002.

10. Duan, Dongsheng, Nathalie Goemans, Shin'ichi Takeda, Eugenio Mercuri, and Annemieke Aartsma-Rus. 2021. "Duchenne Muscular Dystrophy." Nature Reviews Disease Primers 7 (13). https://doi.org/10.1038/s41572-021-00248-3.